BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Jeffrey Robert Ajer sold 1,436 shares of the company’s stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $90.31, for a total value of $129,685.16. Following the completion of the transaction, the executive vice president now directly owns 50,135 shares of the company’s stock, valued at approximately $4,527,691.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Jeffrey Robert Ajer also recently made the following trade(s):

  • On Monday, May 7th, Jeffrey Robert Ajer sold 309 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $85.96, for a total value of $26,561.64.
  • On Monday, April 2nd, Jeffrey Robert Ajer sold 2,119 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $80.12, for a total value of $169,774.28.
  • On Thursday, March 29th, Jeffrey Robert Ajer sold 1,537 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $79.69, for a total value of $122,483.53.
  • On Wednesday, March 21st, Jeffrey Robert Ajer sold 4,368 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $83.90, for a total value of $366,475.20.

Shares of BioMarin Pharmaceutical stock traded up $1.01 on Thursday, reaching $89.98. 1,232,188 shares of the company’s stock were exchanged, compared to its average volume of 1,331,176. The stock has a market capitalization of $15.87 billion, a price-to-earnings ratio of -134.06 and a beta of 1.71. BioMarin Pharmaceutical Inc. has a 52 week low of $75.81 and a 52 week high of $100.03. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.29 and a current ratio of 2.90.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Wednesday, April 25th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.08). The business had revenue of $373.45 million for the quarter, compared to the consensus estimate of $348.73 million. BioMarin Pharmaceutical had a negative return on equity of 3.01% and a negative net margin of 10.48%. BioMarin Pharmaceutical’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.20 earnings per share. equities research analysts forecast that BioMarin Pharmaceutical Inc. will post -0.12 EPS for the current year.

Several institutional investors have recently bought and sold shares of BMRN. Financial Gravity Companies Inc. bought a new position in shares of BioMarin Pharmaceutical during the 4th quarter worth approximately $112,000. Financial Gravity Wealth Inc. bought a new position in shares of BioMarin Pharmaceutical in the 1st quarter worth $195,000. Redmile Group LLC bought a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth $223,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth $224,000. Finally, Gamco Investors INC. ET AL bought a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth $232,000.

BMRN has been the subject of several recent research reports. BidaskClub downgraded BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 24th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, February 27th. Wedbush upped their price objective on BioMarin Pharmaceutical from $112.00 to $115.00 and gave the company an “outperform” rating in a research note on Friday, May 25th. Morgan Stanley upped their price objective on BioMarin Pharmaceutical from $112.00 to $113.00 and gave the company an “overweight” rating in a research note on Monday, April 30th. Finally, Credit Suisse Group reaffirmed a “buy” rating and issued a $116.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, March 29th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $112.50.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.